Federal regulators are expected to authorize the mixing and matching of COVID-19 booster doses this week in an effort to provide flexibility as the campaign for extra shots expands.
Pfizer officially applied for emergency use authorization for its COVID-19 vaccine in kids ages 5-11 today. Here’s more on what the rollout may look like if the vaccine is authorized for that age group.
Pfizer asked the U.S. government Thursday to allow use of its COVID-19 vaccine in children ages 5 to 11 in what would be a major expansion that could combat an alarming rise in serious infections in youngsters and help schools stay open.
Pfizer has submitted research to the U.S. Food and Drug Administration on the effectiveness of its COVID-19 vaccine in children as it moves closer to seeking approval for expanded use of the shots.
The advisory panel to the Centers for Disease Control and Prevention recommended the extra doses for people 65 and older, nursing home residents, and people who are 50 to 64 with underlying medical conditions. It also said boosters can be offered to people 18 to 49 with underlying conditions.
With booster doses of Pfizer’s COVID-19 vaccine now authorized in the U.S., government advisers reconvened on Thursday to tackle the most contentious question yet: Exactly who should roll up their sleeves right away?
President Joe Biden announced Wednesday that the United States is doubling its purchase of Pfizer’s COVID-19 shots to share with the world to 1 billion doses as he embraces the goal of vaccinating 70% of the global population within the next year.
COLUMBIA, SC (WOLO) — Monday brought big news from Pfizer. The drug company announced that Phases 2 and 3 of trials of its COVID-19 vaccine in kids ages 5 to 11 proved to be safe and effective. “Obviously the more kids we get vaccinated, the better off we will be with our herd immunity as well as decreasing spread,” said…
Pfizer said Monday its COVID-19 vaccine works for children ages 5 to 11 and that it will seek U.S. authorization for this age group soon — a key step toward beginning vaccinations for youngsters.
An influential federal advisory panel has soundly rejected a plan to offer Pfizer booster shots against COVID-19 to most Americans. The vote Friday, 61-3, was a blow to the Biden administration’s effort to shore up people’s protection against the virus amid the highly contagious delta variant.
